Showing results (171-180 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|June 12, 2022
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trialNick A de Jonge, Jonne J Sikkens, Sonja Zweegman, et al.
The Lancet. Haematology|April 21, 2019
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studySteven W Pipe, Midori Shima, Michaela Lehle, et al.
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
The Lancet. Haematology|October 22, 2019
The global need and availability of blood products: a modelling studyNicholas Roberts, Spencer James, Meghan Delaney, et al.
The Lancet. Haematology|February 4, 2018
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trialHagop M Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
The Lancet. Haematology|March 18, 2018
Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trialSharon E Cox, Elizabeth A Ellins, Alphonce I Marealle, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
The Lancet. Haematology|December 25, 2017
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trialClaire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, et al.
The Lancet. Haematology|November 5, 2017
Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational studyElizabeth S Allen, Kshitij Srivastava, Matthew M Hsieh, et al.
The Lancet. Haematology|September 30, 2017
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trialAsher A Chanan-Khan, Andrey Zaritskey, Miklos Egyed, et al.
Pageof 73